DDInter900 DDInter1435
Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID. On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Ibuprofen {u} (Compound) resembles {v} (Compound) Carprofen
Ibuprofen {u} (Compound) resembles {v} (Compound) Metyrosine
Ibuprofen {u} (Compound) binds {v} (Gene) SLCO2B1
Ibuprofen {u} (Compound) palliates {v} (Disease) osteoarthritis
Ibuprofen {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Ibuprofen {u} (Compound) causes {v} (Side Effect) Urethral disorder
Ibuprofen {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clove
Ibuprofen {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tacrine
Ibuprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Indomethacin
Ibuprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bedaquiline
Ibuprofen (Compound) resembles Carprofen (Compound)
Ibuprofen (Compound) resembles Metyrosine (Compound)
Ibuprofen (Compound) binds SLCO2B1 (Gene)
Ibuprofen (Compound) palliates osteoarthritis (Disease)
Ibuprofen (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class)
Ibuprofen (Compound) causes Urethral disorder (Side Effect)
Ibuprofen may cause a minor interaction that can limit clinical effects when taken with Clove
Ibuprofen may cause a minor interaction that can limit clinical effects when taken with Tacrine
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline